Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome September 28, 2026 12:30 PM EDT
Company Participants
Brigette Roberts – Chief Corporate Affairs Officer & Director
Keith R. Fandrick – Head of Technical Operations
Conference Call Participants
Aaron Waxman
Paul Yu
Mazahir Alimohamed – Oppenheimer & Co. Inc., Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Samuel Slutsky – LifeSci Capital, LLC
Steven Hays
Olivia Brayer – Cantor Fitzgerald & Co., Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Michael King – Rodman & Renshaw Research
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Gum-Ming Lowe – Craig-Hallum Capital Group LLC, Research Division
Conversation
Operator
Good afternoon, and welcome to the Quince Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be available on the company website following the conclusion of the event.
I will now turn the call over to Dr. Brigette Roberts, Chief Corporate Affairs Officer and Board member at Quince Therapeutics. Please go ahead, Brigette.
Brigette Roberts
Chief Corporate Affairs Officer & Director
Thank you, Wilson. So good afternoon, everyone, and thank you for joining Quince’s KOL event. For those of you who are not yet familiar with this story — let me turn to Slide 3, please. Our company is focused on a proprietary once-daily inhaled formulation of rapamycin called LAM-001 that we’re studying across 3 pulmonary conditions. The first is PH in the setting of interstitial lung disease estimated to affect about 200,000 patients between the U.S. and Europe. Based on promising Phase IIa data that Dr. Paul Yu presented at ATS this year, we have moved forward into a Phase IIb study in PH-ILD with expected data in the first quarter of 2028.
The second indication is bronchiolitis obliterans syndrome post lung
